Table 2 Baseline demographics, risk factors and clinical characteristics
| Â | Male | Female | ||
|---|---|---|---|---|
| Â | Statin (n = 5279) | Statin + EZ (n = 6016) | Statin (n = 5029) | Statin + EZ (n = 5470) |
Mean age, years (SD) | 58.4 (11.22) | 59.2 (11.14) | 60.0 (11.23) | 60.7 (11.01) |
Age, n (%) | Â | Â | Â | Â |
   < 65 years | 3556 (67.4) | 3909 (65.0) | 3126 (62.2) | 3341 (61.1) |
   65-74 years | 1361 (25.8) | 1614 (26.8) | 1457 (29.0) | 1557 (28.5) |
   ≥75 years | 362 (6.9) | 493 (8.2) | 446 (8.9) | 572 (10.5) |
Caucasian, n (%) | 4549 (86.2) | 5187 (86.2) | 4141 (82.3) | 4519 (82.6) |
BMI < 30 kg/m2 (%) | 3287 (63.2) | 3728 (62.8) | 2721 (55.0) | 3056 (56.7) |
CHD, n (%) | 2129 (40.3) | 2614 (43.5) | 1181 (23.5) | 1501 (27.5) |
Diabetes, n (%) | 1491 (28.2) | 1732 (28.8) | 1591 (31.6) | 1727 (31.6) |
Metabolic syndrome | 1912 (46.5) | 2112 (45.8) | 2321 (54.7) | 2406 (53.6) |
Ongoing Statin*, n (%) | 2271 (43.0) | 2935 (48.8) | 1780 (35.4) | 2310 (42.2) |
Least squares mean (SD) | (n = 5279) | (n = 6016) | (n = 5029) | (n = 5470) |
LDL-C (mg/dL) | 147.0 (40.3) | 144.4 (39.8) | 156.4 (41.7) | 154.2 (42.5) |
HDL-C (mg/dL) | 45.8 (10.5) | 45.7 (10.3) | 53.4 (12.7) | 53.7 (13.0) |
non-HDL-C (mg/dL) | 180.2 (44.5) | 177.5 (44.0) | 190.1 (45.8) | 187.6 (46.4) |
TC (mg/dL) | 226.0 (44.0) | 223.2 (43.6) | 243.6 (45.7) | 241.3 (46.2) |
Triglycerides (mg/dL) ‡ | 150.0 (88.1) | 151.0 (87.9) | 156.5 (90.2) | 154.0 (90.7) |
Apo B (mg/dL) | 142.5 (32.7) | 141.3 (32.3) | 147.9 (34.0) | 146.4 (34.4) |
Apo AI (mg/dL) | 146.3 (23.2) | 146.4 (23.8) | 164.2 (27.5) | 165.0 (28.0) |
hs-CRP (mg/L) ‡ | 1.8 (2.7) | 1.8 (2.7) | 2.7 (4.1) | 2.8 (4.1) |
non-HDL-C/HDL-C | 4.1 (1.5) | 4.1 (1.4) | 3.8 (1.4) | 3.7 (1.4) |
Apo B/Apo AI | 1.0 (0.3) | 1.0 (0.3) | 0.9 (0.3) | 0.9 (0.3) |
LDL-C/HDL-C | 3.4 (1.2) | 3.3 (1.2) | 3.1 (1.1) | 3.0 (1.1) |
TC/HDL-C | 5.2 (1.5) | 5.1 (1.4) | 4.8 (1.4) | 4.7 (1.4) |